Genmab Announces Financial Results for the First Quarter of 2022
11/5 17:02
May 11 , 202 2 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2022 Highlights DARZALEX ® net sales as reported by Johnson & Johnson increased 36 % compared to the first three months of 202 1 to USD 1,856 million, resulting in royalty revenue of DKK 1,501 million Genmab...